Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study
Abstract Introduction Patients with ulcerative colitis (UC) are known to have a significantly poor quality of life due to bowel frequency (night) and urgent defecation. Budesonide foam is a topical medication that was approved in Japan in 2017 for the treatment of UC. However, its efficacy in the tr...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-06-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-022-02388-6 |
| _version_ | 1828316184185929728 |
|---|---|
| author | Ryosuke Miyazaki Toshiyuki Sakurai Mariko Shimada Yuko Iwashita Naoki Shibuya Yoshihiro Akita Haruna Miyashita Yuki Maruyama Masayuki Saruta |
| author_facet | Ryosuke Miyazaki Toshiyuki Sakurai Mariko Shimada Yuko Iwashita Naoki Shibuya Yoshihiro Akita Haruna Miyashita Yuki Maruyama Masayuki Saruta |
| author_sort | Ryosuke Miyazaki |
| collection | DOAJ |
| description | Abstract Introduction Patients with ulcerative colitis (UC) are known to have a significantly poor quality of life due to bowel frequency (night) and urgent defecation. Budesonide foam is a topical medication that was approved in Japan in 2017 for the treatment of UC. However, its efficacy in the treatment of bowel frequency (night) or urgent defecation is unknown. This study aimed to explore the efficacy of budesonide foam for the alleviation of these symptoms. Methods UC patients who received budesonide foam between December 2017 and January 2020 at the Jikei University School of Medicine in Tokyo were enrolled. The simple clinical colitis activity index (SCCAI) was evaluated at the start of budesonide foam treatment and 2 and 6 weeks later in patients who initially scored ≥ 1 for bowel frequency (night) and urgent defecation, respectively. We also studied the effect of budesonide foam on remaining symptoms in patients who had used 5-aminosalicylic acid (5-ASA) topical treatment, those with SCCAI ≥ 3, and those in remission with residual symptoms (SCCAI 1 or 2). Results Of the 233 enrolled patients, 102 were eligible for the study. In 36 patients with bowel frequency (night) treated with budesonide foam were significantly effective, score in SCCAI decreased from 1.17 ± 0.45 at baseline to 0.53 ± 0.61 at week 2 (p < 0.0001) and 0.17 ± 0.38 at week 6 (p < 0.0001). In 45 patients with urgent defecation score in SCCAI decreased significantly from 1.33 ± 0.52 at baseline to 0.44 ± 0.59 at week 2 (p < 0.0001) and 0.22 ± 0.40 at week 6 (p < 0.0001). Of 22 patients who switched from topical 5-ASA administration to budesonide foam, nine at week 2 (41%) and 11 (50%) at week 6 were improved with no symptoms, and there were no cases of worsened symptoms. No severe side effects associated with budesonide foam were observed. Conclusion Budesonide foam administration significantly improves both bowel frequency (night) and urgent defecation-related UC activity and is also effective for the patients who were refractory to topical 5-ASA administration. |
| first_indexed | 2024-04-13T17:11:11Z |
| format | Article |
| id | doaj.art-db77b0ffadbe4ff191c98d9d45052e72 |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-04-13T17:11:11Z |
| publishDate | 2022-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-db77b0ffadbe4ff191c98d9d45052e722022-12-22T02:38:17ZengBMCBMC Gastroenterology1471-230X2022-06-012211710.1186/s12876-022-02388-6Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational studyRyosuke Miyazaki0Toshiyuki Sakurai1Mariko Shimada2Yuko Iwashita3Naoki Shibuya4Yoshihiro Akita5Haruna Miyashita6Yuki Maruyama7Masayuki Saruta8Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of MedicineDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of MedicineDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of MedicineDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of MedicineDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of MedicineDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of MedicineDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of MedicineDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of MedicineDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of MedicineAbstract Introduction Patients with ulcerative colitis (UC) are known to have a significantly poor quality of life due to bowel frequency (night) and urgent defecation. Budesonide foam is a topical medication that was approved in Japan in 2017 for the treatment of UC. However, its efficacy in the treatment of bowel frequency (night) or urgent defecation is unknown. This study aimed to explore the efficacy of budesonide foam for the alleviation of these symptoms. Methods UC patients who received budesonide foam between December 2017 and January 2020 at the Jikei University School of Medicine in Tokyo were enrolled. The simple clinical colitis activity index (SCCAI) was evaluated at the start of budesonide foam treatment and 2 and 6 weeks later in patients who initially scored ≥ 1 for bowel frequency (night) and urgent defecation, respectively. We also studied the effect of budesonide foam on remaining symptoms in patients who had used 5-aminosalicylic acid (5-ASA) topical treatment, those with SCCAI ≥ 3, and those in remission with residual symptoms (SCCAI 1 or 2). Results Of the 233 enrolled patients, 102 were eligible for the study. In 36 patients with bowel frequency (night) treated with budesonide foam were significantly effective, score in SCCAI decreased from 1.17 ± 0.45 at baseline to 0.53 ± 0.61 at week 2 (p < 0.0001) and 0.17 ± 0.38 at week 6 (p < 0.0001). In 45 patients with urgent defecation score in SCCAI decreased significantly from 1.33 ± 0.52 at baseline to 0.44 ± 0.59 at week 2 (p < 0.0001) and 0.22 ± 0.40 at week 6 (p < 0.0001). Of 22 patients who switched from topical 5-ASA administration to budesonide foam, nine at week 2 (41%) and 11 (50%) at week 6 were improved with no symptoms, and there were no cases of worsened symptoms. No severe side effects associated with budesonide foam were observed. Conclusion Budesonide foam administration significantly improves both bowel frequency (night) and urgent defecation-related UC activity and is also effective for the patients who were refractory to topical 5-ASA administration.https://doi.org/10.1186/s12876-022-02388-6Budesonide foamBowel frequency (night)Urgent defecation5-ASA topical treatment |
| spellingShingle | Ryosuke Miyazaki Toshiyuki Sakurai Mariko Shimada Yuko Iwashita Naoki Shibuya Yoshihiro Akita Haruna Miyashita Yuki Maruyama Masayuki Saruta Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study BMC Gastroenterology Budesonide foam Bowel frequency (night) Urgent defecation 5-ASA topical treatment |
| title | Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study |
| title_full | Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study |
| title_fullStr | Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study |
| title_full_unstemmed | Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study |
| title_short | Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study |
| title_sort | bowel frequency night and urgent defecation are improved by budesonide foam in patients with ulcerative colitis a retrospective observational study |
| topic | Budesonide foam Bowel frequency (night) Urgent defecation 5-ASA topical treatment |
| url | https://doi.org/10.1186/s12876-022-02388-6 |
| work_keys_str_mv | AT ryosukemiyazaki bowelfrequencynightandurgentdefecationareimprovedbybudesonidefoaminpatientswithulcerativecolitisaretrospectiveobservationalstudy AT toshiyukisakurai bowelfrequencynightandurgentdefecationareimprovedbybudesonidefoaminpatientswithulcerativecolitisaretrospectiveobservationalstudy AT marikoshimada bowelfrequencynightandurgentdefecationareimprovedbybudesonidefoaminpatientswithulcerativecolitisaretrospectiveobservationalstudy AT yukoiwashita bowelfrequencynightandurgentdefecationareimprovedbybudesonidefoaminpatientswithulcerativecolitisaretrospectiveobservationalstudy AT naokishibuya bowelfrequencynightandurgentdefecationareimprovedbybudesonidefoaminpatientswithulcerativecolitisaretrospectiveobservationalstudy AT yoshihiroakita bowelfrequencynightandurgentdefecationareimprovedbybudesonidefoaminpatientswithulcerativecolitisaretrospectiveobservationalstudy AT harunamiyashita bowelfrequencynightandurgentdefecationareimprovedbybudesonidefoaminpatientswithulcerativecolitisaretrospectiveobservationalstudy AT yukimaruyama bowelfrequencynightandurgentdefecationareimprovedbybudesonidefoaminpatientswithulcerativecolitisaretrospectiveobservationalstudy AT masayukisaruta bowelfrequencynightandurgentdefecationareimprovedbybudesonidefoaminpatientswithulcerativecolitisaretrospectiveobservationalstudy |